Vol. 1 No. 5 (2026), Articles
Vol. 1 No. 5 (2026)

Early Diagnosis and Prognosis of Hereditary Breast Cancer

Articles
Published 2026-05-24
Baxramova Gulzirabonu
Master's Student, Department of General Oncology, Andijan State Medical Institute
Djalolova Feruza
PhD, Department of Oncology, Andijan State Medical Institute

Keywords

Hereditary breast cancer, BRCA mutations, early diagnosis, MRI, PARP inhibitors, genetic screening, precision oncology.

How to Cite

Baxramova Gulzirabonu, & Djalolova Feruza. (2026). Early Diagnosis and Prognosis of Hereditary Breast Cancer. KLINIK VA FUNDAMENTAL TIBBIYOT TADQIQOTLARI JURNALI, 1(5), 59-63. https://innopublication.com/index.php/jcmfr/article/view/599
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver AMA

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

Hereditary breast cancer (HBC), driven by highly penetrant mutations in genes like BRCA1/2, TP53, and PALB2, represents an aggressive oncological subset. This review highlights the necessary paradigm shift from generalized screening to individualized, genetically-guided surveillance. The integration of high-resolution MRI and next-generation sequencing (NGS) has transformed early detection, identifying micro-malignancies long before mammographic visibility. Furthermore, targeted pharmacotherapies, notably PARP inhibitors exploiting homologous recombination deficiency (HRD), have radically redefined HBC prognosis. Ultimately, integrating precision oncology and comprehensive genetic counseling is imperative to mitigate phenotypic risks and optimize long-term survivorship.

References

1. Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.

2. Tung N, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016;34(13):1460-1468.

3. Riedl CC, et al. Triple-Modality Screening Trial for Familial Breast Cancer Underlines the Importance of Magnetic Resonance Imaging. J Clin Oncol. 2015;33(10):1128-1135.

4. Tutt ANJ, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021;384(25):2394-2405.

5. Litton JK, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018;379(8):753-763.

6. Daly MB, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. J Natl Compr Canc Netw. 2021;19(1):77-102.

7. Fasching PA, et al. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer. J Clin Oncol. 2018;36(22):2281-2287.

8. Hartmann LC, Lindor NM. The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med. 2016;374(5):454-468.

9. Robson M, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017;377(6):523-533.